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Background: Cardiovascular (CVS) comorbidities are common in COPD and contribute 
significantly to morbidity and mortality, especially following acute exacerbations of COPD 
(AECOPD). Beta-blockers (BBs) are safe and effective in COPD patients, with demonstrated 
survival benefit following myocardial infarction. We sought to determine if BBs are under-
prescribed in patients hospitalized with AECOPD. We also sought to determine inpatient rates 
of CVS and cerebrovascular complications, and their impact on patient outcomes.
Methods: Retrospective hospital data was collected over a 12-month period. The medical 
records of all patients 40 years of age coded with a diagnosis of AECOPD were analyzed. 
Prevalent use and incident initiation of BBs were assessed. Comorbidities including indications 
and contraindications for BB use were analyzed.
Results: Of the 366 eligible patients, 156 patients (42.6%) had at least one indication for BB 
use – of these patients, only 53 (34.0%) were on BB therapy and 61 (39.1%) were not on BB 
therapy but had no listed contraindication. Prevalent use of BBs at the time of admission in all 
366 patients was 19.7%, compared with 45.6%, 39.6% and 45.9% use of anti-platelets, statins 
and angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers, respectively. CVS 
and cerebrovascular complications were common in this population (57 patients, 16%) and were 
associated with longer length of stay (p,0.01) and greater inpatient mortality (p=0.02).
Conclusions: BBs are under-prescribed in COPD patients despite clear indication(s) for their 
use. Further work is required to explore barriers to BB prescribing in COPD patients.
Keywords: COPD exacerbations, beta-blockers, cardiovascular, comorbidity
Introduction
COPD remains a major cause of mortality and morbidity across the world. The World 
Health Organization listed COPD as the fourth leading cause of death worldwide 
(alongside lower respiratory infections) in 2015, resulting in an estimated 3.17 million 
deaths that year.1
Acute exacerbations of COPD (AECOPD) carry a poor prognosis with a calculated 
1- and 2-year mortality of 22% and 36%, respectively.2,3 Patients with frequent exac-
erbations have more than 4 times risk of death compared with non-exacerbators.4
There is increasing focus in medical literature on COPD comorbidities.5–8 The 
Global Initiative for Chronic Obstructive Lung Disease guidelines (2016) dedicate 
a full chapter to the management of comorbidities in COPD, emphasizing their 
importance.7 COPD patients are at higher risk of CVS disease. CVS disease is 
associated with high morbidity and mortality in COPD patients.8–10 The ECLIPSE 
group showed that CVS disease was an independent risk factor for mortality after 
adjusting for age, gender and smoking history in their cohort of 2,164 patients.9 The 
estimated mortality hazard ratio of having concurrent heart failure (HF) in COPD 
patients compared with those without HF is 1.3–1.9; concurrent ischemic heart disease 
(IHD) has a hazard ratio of 1.27–1.5; and concurrent atrial fibrillation/flutter has a 
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hazard ratio of 1.56.8–10 The optimum management of CVS 
comorbidities in COPD has not been fully ascertained.
Beta-blockers (BBs) have proven mortality benefit in 
patients with IHD and HF.11–14 Subgroup analysis of post-
myocardial infarction (post-MI) patients has shown a consis-
tent beneficial effect in patients with concurrent COPD.11,12 
Registry data also points to improved survival in post-MI 
COPD patients initiated early on beta-blockade therapy.15 
There may even be beneficial effects of BBs in COPD patients 
independent from CVS effects. Indeed, in a Scottish retro-
spective cohort study conducted in 2011 by Short et al using 
the TARDIS database, use of BBs was associated with 22% 
reduction in all-cause mortality as well as reduction in need of 
emergency oral corticosteroid use and hospital admissions.16
There has previously been debate about the safety of 
BBs in patients with COPD. A Cochrane meta-analysis con-
ducted in 2011 demonstrated the safety of BB use in COPD, 
showing no significant change in forced expiratory volume 
in 1 s (FEV
1
), respiratory symptoms or FEV
1
 response to 
bronchodilators when compared with placebo.17 This includes 
COPD patients with FEV
1
 ,50% predicted or 1.4 L and 
those with reversible airflow limitation. Nevertheless, there 
remains a persisting reluctance from physicians to prescribe 
BBs in COPD patients primarily because of the perceived 
risk of inducing bronchospasm.
aims
In order to determine local prescribing practices of BBs, 
we examined hospital inpatients at a major tertiary hospital 
admitted with an AECOPD. The primary aim of the study 
was to measure prevalent rates at time of hospitalization of 
appropriate BB use in this group of COPD patients. We also 
sought to determine the rates of CVS and cerebrovascular 
(CVA) events during acute COPD exacerbation admissions, 
and examined their impact on hospital length of stay, inten-
sive care unit (ICU) admissions and in-patient mortality.
Methods
We conducted a retrospective cohort study on patients 40 
years of age admitted with AECOPD over 1 year (1 January 
2012 to 31 December 2012) in a large tertiary metropolitan 
hospital. For patients with repeat admissions during the 
year, only the first admission was included in the analysis. 
Data was collected from hospital electronic databases and 
discharge summaries.
Appropriate use of BBs was defined as having at least 
1 indication for use in the absence of contraindications. 
We defined indications for BB therapy as having a history of 
IHD, congestive cardiac failure (CCF) and tachyarrhythmias. 
Contraindications included a history of BB allergy, bra-
dyarrhythmias, asthma, peripheral vascular disease and 
hypotension.
IHD events included any of the following: ST-elevation 
MI, non-ST elevation MI, unstable angina or stable angina. 
CVA events included ischemic stroke, hemorrhagic stroke 
and transient ischemic attack.
This project was approved by the Royal Perth Hospital 
Human Research Ethics Committee (EC00270/HREC REG 
14–045). The Committee approved waiver of patient consent, 
as this was classified a negligible-risk study. De-identified 
data was used throughout the study.
Statistical analysis was performed on Stata® software. 
Student’s independent t-test, Chi square and Fisher’s exact 
tests were used for inter-group comparisons with an alpha-
error cutoff of 0.05.
Results
A total of 572 admissions were retrieved on initial clinical 
coding screen. 366 patients were included in the data analysis 
(Figure 1). The basic patient demographics and clinical out-
comes are shown in Table 1.
Prevalence of appropriate use of BBs at 
the time of admission
The prevalence of BB use on admission was 19.7% (72 of 
366). Of all patients, 42.6% (156 of 366) had at least 1 indica-
tion for BB use. Of these patients, 34.0% (53 of 156) were 
on BBs, 39.1% (61) were not on BBs and had no known 
contraindications for their use, and 26.9% (42) were not on 
BBs and had known potential contraindications (Figure 1). 
The breakdowns of the indications and contraindications to 
BB use are listed in Table 2.
Cardioselective and non-cardioselective 
BBs
Sixty-two out of the 72 (86.1%) patients on BB therapy at the 
time of admission were on cardioselective BBs (metoprolol 
28, bisoprolol 18, atenolol 11, nebivolol 5). The 8 patients 
who were initiated on BB therapy during their admission were 
all commenced on cardioselective BBs (metoprolol 8).
Table 1 Patient demographics and clinical outcomes
number of males/females: 208/158 (ratio 1.3:1)
Mean age: 72.7 years (±12.1 sD)
Mean length of stay: 5.1 days (±5.5 sD)
Median length of stay: 3 days (interquartile range =2–6)
number of ICU admissions: 7 (1.9%)
number of deaths: 11 (3.0%)
Abbreviation: ICU, intensive care unit.
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Inter-group analyses
We performed inter-group outcome analyses to detect trends. 
It is important to note that these analyses were not adjusted 
for confounders and the study was not powered to detect 
outcome differences.
We compared the outcomes between AECOPD patients on 
BB therapy on admission (n=72) and patients not on BB therapy 
on admission (n=294). There were more in-hospital incident 
CCF events in the on-therapy group (p,0.01) compared with 
the off-therapy group. However, patients in the on-therapy 
group were also more likely to have a history of HF (p,0.01) 
or IHD (p,0.01). There were no statistically significant differ-
ences in length of stay, mortality, intensive care admissions, or 
in-hospital incident tachyarrhythmia, IHD or CVA events.
We then compared the outcomes between AECOPD 
patients with at least 1 indication for BB use and were appro-
priately on BB (n=53), and patients with at least 1 indication 
and no contraindication but were inappropriately not on 
BB (n=61). In the mortality analysis, there were fewer deaths 
in the appropriately treated group (0 out of 53) compared 
with the group that were inappropriately not on BB therapy 
(6 out of 61), but this did not reach statistical significance 
(p=0.063 by Fisher’s exact test). There were no statistically 
significant differences in length of stay, or in-hospital inci-
dent tachyarrhythmia, IHD, CCF or CVA events.
CVs drug prescribing patterns
We compared the prescribing practices of BBs compared 
with other CVS drugs. 19.7% of patients with AECOPD 
were prescribed BBs, while 45.6% were on anti-platelet 
medications, 39.6% on statins and 45.9% on angiotensin-
converting enzyme inhibitor/angiotensin II receptor blockers 
(ACEi/ARBs) (Table 3). In patients with a documented 
???????????????????????????????????????????
??????????????????????????????????????????? ????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????
?????????????????????????????????????????
???????????????
???????????????????????
Figure 1 COnsOrT diagram.
Note: Text/data shown in bold are the important points.
Abbreviation: BB, beta-blocker.
Table 2 Indications and contraindications for beta-blocker use
Percentage of 
patients, % (n=366)
Indications
Ischemic heart disease 33.1 (121)
Congestive cardiac failure 15.8 (58)
Tachyarrhythmias 11.2 (41)
At least 1 indication 42.6 (156)
More than 1 indication 15.0 (55)
Contraindications
Beta-blocker allergy 0.3 (1)
asthma 17.8 (65)
Peripheral vascular disease 5.7 (21)
Bradyarrhythmias 7.7 (28)
hypotension 3.0 (11)
At least 1 contraindication 31.7 (116)
Note: Values shown in bold are the important points.
Table 3 Prevalent use of cardiovascular drugs in aeCOPD patients
Beta-
blocker, %
Anti-platelet 
drug, %
Statin, % ACEi/
ARB, %
% baseline use 
in all aeCOPD 
patients (n=366)
19.7 45.6 39.6 45.9
% prevalent use 
in patients with 
incident IhD 
events (n=25)
16 48 44 44
% prevalent use 
in patients with 
previous history 
of IhD (n=16)
25 75 68.8 68.8
Abbreviations: aCei, angiotensin converting enzyme inhibitor; aeCOPD, acute 
exacerbation of chronic obstructive pulmonary disease; arB, angiotensin II receptor 
blocker; IhD, ischemic heart disease.
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history of IHD, the prevalence of BB use was 25%, com-
pared with 75% anti-platelet use, 68.8% statin use and 68.8% 
ACEi/ARB use.
Patients with incident IhD events during 
admission
Twenty-five out of 366 patients (6.8%) had an incident IHD 
event during their inpatient stay. Sixteen of the 25 patients 
(64%) had a prior history of IHD; however, only 4 out of the 
25 patients (16%) were on BB therapy. In treatment-naïve 
patients with new IHD events, 14.3% were commenced on a 
BB during the admission, compared with 76.9% commenced 
on anti-platelet therapy (Table 4).
CVs and CVa events
CVS and CVA events occurred frequently in our cohort of 
AECOPD patients. Fifty-seven out of 366 patients (15.6%) 
had CVS and/or CVA events during their admission. A total 
of 70 CVS/CVA events were identified: CCF exacerbations 
were the most common (27), followed by IHD events (25), 
tachyarrhythmias (16) and strokes (2).
In-hospital CVS/CVA events were associated with a 
longer mean hospital length of stay (7.3 days vs 4.7 days, 
p,0.01) and a higher inpatient mortality (8.8% vs 1.9%, 
p=0.02; Figure 2). A greater percentage of patients with 
CVS/CVA events had ICU admissions (5.2% vs 1.3%, 
p=0.13), but this was not statistically significant.
Discussion
Our results show that BBs are under used in patients 
admitted with AECOPD despite indication(s) for their use. 
Some of these patients had significant cardiac histories 
with no contraindication for use. This highlights a disparity 
between the existing evidence base and routine clinical prac-
tice, which may be detrimental to the care of this high-risk 
group of patients.
Our results complement those described by Neef et al in a 
separate Australian state, which showed only 51% of patients 
with a history of heart failure with reduced ejection fraction 
and COPD, and 31% of patients with a history of previous 
MI and COPD, were on BBs at the time of admission.18
The prevalent use of CVS drugs were comparable with 
the UK EXODUS cohort reported by Harrison et al – 17% 
of patients were on BBs at baseline, 42% statins, 50% ACEi/
ARBs, 46% aspirin and 7% clopidogrel in the EXODUS 
cohort (n=1,343) compared with 20% BBs, 40% statins, 
46% ACEi/ARBs and 46% anti-platelets (any) in our cohort 
(n=366).19 This indicates that BB under-prescribing is not an 
isolated problem and perhaps reflects physicians’ persistent 
hesitancy in prescribing BBs in COPD patients.
Furthermore, our data shows that the under-use of BB 
therapy holds true in patients with new cardiac events during 
their admission for AECOPD. BBs are poorly prescribed 
compared with other CVS drug classes, suggesting ongoing 
hesitancy regarding safety of initiation in COPD patients. 
A COPD patient suffering an inpatient IHD event is 5.5 times 
more likely to be started on an anti-platelet agent than a BB. 
This shows a deviation from evidence-based practice.
Our cohort had a high prevalence (~1 in 6) of CVS or CVA 
events during their admission and this resulted in increased 
mortality and length of stay. These findings are consistent 
with previous studies, which also indicate a startlingly high 
frequency of these events.6–10 Donaldson et al report incidence 
rates of 1.1 MIs per 100 patient-years and 1.4 stroke per 
100 patient-years in a cohort of 25,857 COPD exacerbation 
patients.20 Cause-specific mortality analysis of the TORCH 
Table 4 Initiation of cardiovascular drugs in aeCOPD patients 
with new IhD events
n=25 Beta-
blocker
Anti-platelet 
drug
Statin ACEi/ARB
% incident initiation of 
therapy in treatment-
naïve patients
14.3%
(3 of 21)
76.9%
(10 of 13)
28.6%
(4 of 14)
14.3%
(2 of 14)
Abbreviations: aCei, angiotensin converting enzyme inhibitor; aeCOPD, acute 
exacerbation of chronic obstructive pulmonary disease; arB, angiotensin II receptor 
blocker; IhD, ischemic heart disease.
?????????????????????????
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Figure 2 Clinical endpoints for AECOPD patients stratified by incidence of 
cardiovascular or cerebrovascular events.
Abbreviations: aeCOPD, acute exacerbation of chronic obstructive pulmonary 
disease; CVs, cardiovascular; CVa, cerebrovascular; ICU, intensive care unit.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
20
3.
19
.8
1.
25
0 
on
 1
7-
Ap
r-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3045
Beta-blocker under-use in COPD patients
study cohort indicated that 27% of the 911 deaths were attrib-
uted to CVS causes.21 Indeed, it has been shown that cardiac 
dysfunction during COPD exacerbations and arrhythmogenic 
sympathetic activation may be major contributors to morbidity 
and should be viewed as an important therapeutic targets.22,23
There is some evidence from observational data that 
BBs in COPD may reduce all-cause mortality or at least 
improve outcomes, including exacerbation frequency.13–18,24,25 
Perhaps there is a role for BBs in all COPD patients. There 
is an ongoing prospective multi-center, double-blinded, 
placebo-controlled randomized trial (βLOCK COPD) recruit-
ing moderate-to-severe COPD patients with no absolute 
indication for BB therapy to treatment with metoprolol vs 
placebo with the primary outcome measure being time to 
first exacerbation of COPD (secondary outcomes include 
frequency of exacerbations and mortality).26
The management of COPD comorbidities is vital in the 
overall optimal treatment algorithm of the disease. Safe and 
effective use of cardioselective BBs in COPD patients is 
likely going to be an important piece of the puzzle. The cor-
rect choice of BB is likely to be crucial.27–29 There may also 
be a subset of severely unwell patients in whom BB initiation 
carries higher risk of morbidity.29,30
Limitations
We accept that there are limitations to this study. First, 
this is a retrospective study looking primarily at electronic 
discharge summaries and medication prescriptions. Second, 
the diagnoses labeled were clinical or historical. We did not 
have full data on spirometric diagnosis of COPD nor did we 
have echocardiogram reports on severity of left ventricular 
dysfunction. Third, our definitions on contraindications were 
intentionally broad. While this may overestimate the true 
prevalence of contraindications to BBs, it was intentional so 
that any bias would be toward the null hypothesis. Finally, 
we also intentionally excluded hypertension as an indication 
for BB therapy so as not to overestimate the under-utilization 
of BBs. Although BBs are often used for this indication, 
there are other classes of medication that may be used in 
its place.
Our data adds to evidence of BB under-prescribing in 
this high-risk population of patients. It indicates the need to 
review prescribing practices in COPD patients with cardiac 
comorbidities. We suggest: 1) Regular audit of BB and 
CVS drugs prescribing practices in COPD patients in both 
inpatient and outpatient settings. 2) Education across other 
medical specialties about the safety and potential benefits 
of BBs in COPD patients. 3) Safety and governance review 
of BB-associated morbidity in COPD patients to identify 
potential subgroups who may not be suitable for this line 
of treatment. 4) Collaborative research toward defining the 
optimal place of BB therapy in COPD management. This 
should include studies on secondary and tertiary prevention 
of comorbid CVS events, longitudinal cohort studies to assess 
long-term safety profiles of therapy, and intervention trials 
with relevant clinical outcomes like mortality, exacerbation 
frequency, rate of lung function decline and CVS or non-
CVS morbidity.
The take-away message is: if a COPD patient has an 
absolute indication for BB use (and no contraindication), 
consider prescribing one.
Disclosure
The authors report no conflicts of interest in this work.
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